Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis
Asia-Pacific Journal of Clinical Oncology · 08.04.2026
DOI: 10.1111/ajco.70108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, online erschienen am 08.04.2026. Verfasst von Louise Nott und 8 weiteren Autor:innen. Beteiligte Einrichtung: Icon Cancer Centre Hobart, Hobart, Tasmania, Australia. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer Australia Pty Ltd.
Abstract (Originalsprache)
Background
There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer. This study describes the demographic and clinical characteristics of patients initiating CDK4/6 inhibitors, and analyses of real‐world treatment patterns and outcomes with palbociclib, including dose modifications, time to chemotherapy initiation, and duration of treatment.
Methods
This non‐interventional retrospective cohort study from Australia used the Pharmaceutical Benefits Scheme dataset, which includes longitudinal claims data from January 2004 to December 2023. The study population comprised CDK4/6i‐naïve patients aged ≥ 18 years initiating first treatment with a CDK4/6 inhibitor between June 2018 and December 2023. Comorbidities were determined using the validated Rx‐Risk Comorbidity Index. Descriptive data analyses were conducted, and the Kaplan–Meier method was used for time‐to‐event analyses.
Results
The study analyzed data from 1128 patients, including 407 initiating palbociclib. The median age at palbociclib initiation was 67 years, with 67% aged > 60 years. Sixty seven percent of patients had received treatment for ≥ 3 comorbidities in the preceding 12 months. 80% of patients started on the 125‐mg formulation, and 53% did not undergo a dose modification (all initiated doses). At a median follow‐up of 38 months, 61% and 40% remained on treatment with palbociclib at 12 and 24 months, respectively. Median duration of treatment was 541 days (18 months) and median time to chemotherapy was not reached.
Conclusions
This study provides real‐world data on the utilization and outcomes of palbociclib in Australia, complementing data from randomized clinical trials and offering insights into the management of HR+/HER2‐ advanced or metastatic breast cancer. Trial Registration ClinicalTrials.Gov identifier: NCT06624020
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Icon Cancer Centre Hobart, Hobart, Tasmania, Australia.
- Liverpool Hospital, Liverpool, New South Wales, Australia.
- St Vincent's Private Hospital Northside, Queensland, Australia.
- Pfizer Australia and New Zealand, Sydney, New South Wales, Australia.
- IQVIA Solutions Pty Limited, Sydney, New South Wales, Australia.
- St Vincent's Private Hospital, Melbourne, Victoria, Australia.
Förderung
- Pfizer Australia Pty Ltd
Zitieren
APA
Nott, L., Moylan, E., Colosimo, M., Stratton, G., Chiu, T., Kouhkamari, M. H., Hitschfeld, M., Michie, J., & De Boer, R. (2026). Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.70108
Vancouver
Nott L, Moylan E, Colosimo M, Stratton G, Chiu T, Kouhkamari MH, et al. Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis. Asia-Pacific Journal of Clinical Oncology. 2026. doi:10.1111/ajco.70108
BibTeX
@article{Nott2026,
author = {Nott, Louise and Moylan, Eugene and Colosimo, Maree and Stratton, Giles and Chiu, Thomas and Kouhkamari, Mahsa H and Hitschfeld, Maureen and Michie, Jessica and De Boer, Richard},
title = {Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
doi = {10.1111/ajco.70108}
}
EUVIMED